Archive August 13, 2019 Deciphera Pharmaceuticals Announces Positive Top-line Results from INVICTUS Pivotal Phase 3 Clinical Study of Ripretinib in Patients with Advanced Gastrointestinal Stromal Tumors
Archive August 2, 2019 Deciphera Pharmaceuticals, Inc. Announces Second Quarter 2019 Financial Results
Archive July 8, 2019 Deciphera Pharmaceuticals, Inc. Announces Appointment of Susan L. Kelley, M.D., to its Board of Directors
Archive June 11, 2019 Deciphera Pharmaceuticals, Inc. and Zai Lab Limited Announce an Exclusive License Agreement for Ripretinib in Greater China
Archive June 10, 2019 Deciphera Pharmaceuticals, Inc. Expands Pipeline with Potential First-in-Class Autophagy Inhibitor to Treat Mutant RAS Cancers
Archive May 30, 2019 Deciphera Pharmaceuticals, Inc. to Present at the Jefferies Global Healthcare Conference
Archive May 14, 2019 Deciphera Pharmaceuticals, Inc. to Present at the UBS Global Healthcare Conference
Archive March 14, 2019 Deciphera Pharmaceuticals, Inc. Announces Fourth Quarter and Year-end 2018 Financial Results
Archive March 4, 2019 Deciphera Pharmaceuticals, Inc. Announces Retirement of Michael D. Taylor, Ph.D.
